zhengguangmycin and Lung-Neoplasms

To evaluate the clinical value of (99m)Tc-Pingyangmycin (PYM) imaging for the diagnosis of primary lung cancer.. Radionuclide (99m)Tc-Pingyangmycin (PYM) imaging was performed in 56 patients with pulmonary lesions.. The uptake ratio and retention index (RI) were different in malignant and benign lesions. With the delayed ratio regarded as the threshold for lung cancer, the overall accuracy, sensitivity and specificity of (99m)Tc-PYM in the diagnosis of lung cancer were 82.1%, 82.7% and 80%, respectively. If RI was regarded as the threshold, the overall accuracy, sensitivity and specificity were 94.6%, 93% and 100%, respectively. There was no significant difference among different histological types of the lung carcinoma.. (99m)Tc-PYM, as a good imaging agent, is useful in differentiating malignant lung lesions from benign ones.

Topics: Adult; Bleomycin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Technetium; Tomography, Emission-Computed, Single-Photon

A simple method of preparation of 99mTc-pingyangmycin (PYM) for clinical use has been established using super-micro-amounts of SnCl2 as a reductant under dark conditions. The labeling efficiency was higher than 96%, and further purification was not necessary. The effect of ascorbic acid on the distribution of 99mTc-PYM had been investigated. Ascorbic acid increased uptake of 99mTc-PYM in the tumor. Tumor uptake increased with increasing concentration of ascorbic acid. Tumor-blood, tumor-liver, tumor-lung ratios at 1.5 h after 99mTc-PYM administration were 5.19 +/- 1.64, 2.71 +/- 0.51 and 4.15 +/- 0.57, respectively. Preliminary clinical trials in nine patients showed that 99mTc-PYM is a potentially useful tracer for tumor detection with good sensitivity and specificity (true positive 7/7, true negative 1/1, and false positive 1/1).

Topics: Aged; Animals; Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Ehrlich Tumor; Carcinoma, Squamous Cell; Drug Stability; Female; Humans; Isotope Labeling; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Middle Aged; Organotechnetium Compounds; Radiography; Radionuclide Imaging; Technetium; Tissue Distribution

The primary donor tumor was a spontaneous mammary tumor which arose in a 348-day-old female TA2 mouse. The pedigree number of that mouse was 0901-1423. The mouse was sacrificed for serial s.c. transplantation with 3 isogeneic hosts on January 19, 1989 and a total of 27 generations succeeded by the end of April, 1992. The primary donor tumor was diagnosed pathologically as a type B mouse mammary adenocarcinoma (Dunn 1959). The incidence of this serial s.c. transplantation tumor is 100% after inoculation. The latency period is 4-7 days and the lifetime of tumorbearing mice is about 47 days. The spontaneous metastatic rates in the lungs was 100% after the 11th generations. The earliest metastasis seen in the lung under light microscopy was on the 10th day after inoculation, and the earliest seen by gross examination was on about the 35th day. The transplanted tumor grew slowly from the 4th day to the 21st day after inoculation and then grew rather fast from the 22nd to the 47th day. The average size of the transplanted tumor obtained from 10 recipient mice on the 47th day after inoculation was 4.93cm3. Seven anticancer drugs were administered respectively for a sensitivity test. The taking rates of the transplanted tumor using 4 of the 7 drugs were as follows: 5-fluorouracil 29.27% (P < 0.05); thio-tepa 44.80% (P < 0.01); cyclophosphamide 95.31% (P < 0.01); and bleomycin 96.27% (P < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Disease Models, Animal; Female; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Neoplasm Transplantation

Pingyangmycin (PYM), produced by Streptomyces pingyangensis n. sp., was found to be identical to bleomycin A5. In the present study, a comparative observation was carried out in 10 human cancer cell lines. As determined by a colony-forming assay, the dose-response curves obtained from cells exposed to PYM for 1 h were of one type only: biphasic exponential. The sensitivities of these cells derived from different types of tumors, however, varied with a broad range of ID50 values (0.03-0.82 microgram/ml). A hepatoma cell line (BEL-7402) and three lines derived from squamous carcinomas of the esophagus (Eca109 and CaEs17) or the nasopharynx (CNE) were relatively sensitive (ID50 less than 0.20 microgram/ml) to PYM which is known to have clinical activity against these diseases. Two gastric adenocarcinoma cell lines (MGc80-3 and BGC-823) and a pulmonary adenocarcinoma cell line (SPC-A-1) appeared to be less sensitive to the drug, with ID50 values of 0.21-0.47 microgram/ml. PYM was 7-fold more effective against LTEP-78 cells derived from pulmonary squamous carcinoma as opposed to SPC-A-1 cells, resulting in a low ID50 value of 0.04 microgram/ml. However, PYM as a single agent has not yet received full evaluation in relation to this type of lung cancer. In contrast with other cell lines of squamous cancer origin, HeLa and CC-801 cells derived from uterine cervix carcinomas which have been evaluated as highly responsive to PYM had the highest ID50 values (greater than 0.70 microgram/ml).

Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Humans; Liver Neoplasms; Lung Neoplasms; Nasopharyngeal Neoplasms; Tumor Cells, Cultured; Tumor Stem Cell Assay; Uterine Cervical Neoplasms